Get the Stockscreener App
6.90
2.13%
-0.15
Igm Biosciences Inc stock is traded at $6.90, with a volume of 419.38K.
It is down -2.13% in the last 24 hours and down -29.34% over the past month.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
See More
Previous Close:
$7.05
Open:
$6.88
24h Volume:
419.38K
Relative Volume:
1.53
Market Cap:
$410.30M
Revenue:
$2.91M
Net Income/Loss:
$-220.40M
P/E Ratio:
-1.3093
EPS:
-5.27
Net Cash Flow:
$-176.15M
1W Performance:
-3.77%
1M Performance:
-29.34%
6M Performance:
+5.99%
1Y Performance:
-12.21%
1-Day Range:
$6.755
$7.50
1-Week Range:
$6.755
$7.86
52-Week Range:
$6.1721
$22.50
Igm Biosciences Inc Stock (IGMS) Company Profile
Name
Igm Biosciences Inc
Sector
Industry
Phone
650-965-7873
Address
325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW
Compare IGMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IGMS
Igm Biosciences Inc
|
6.90 | 410.30M | 2.91M | -220.40M | -176.15M | -3.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Igm Biosciences Inc Stock (IGMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-01-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-24 | Downgrade | Truist | Buy → Hold |
| Feb-09-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-07-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-09-22 | Resumed | Jefferies | Buy |
| Oct-17-22 | Initiated | JP Morgan | Neutral |
| Aug-29-22 | Initiated | BofA Securities | Buy |
| Dec-13-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-05-21 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-26-21 | Initiated | Morgan Stanley | Overweight |
| Jan-29-21 | Initiated | RBC Capital Mkts | Outperform |
| Jan-19-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-22-20 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-17-20 | Initiated | Robert W. Baird | Outperform |
| Jul-01-20 | Initiated | H.C. Wainwright | Buy |
| May-28-20 | Initiated | SunTrust | Buy |
| Apr-22-20 | Initiated | Wedbush | Outperform |
| Oct-14-19 | Initiated | Guggenheim | Buy |
| Oct-14-19 | Initiated | Jefferies | Buy |
| Oct-14-19 | Initiated | Piper Jaffray | Overweight |
| Oct-14-19 | Initiated | Stifel | Buy |
View All
Igm Biosciences Inc Stock (IGMS) Latest News
IGM Biosciences, Inc. (NASDAQ:IGMS) CEO Mary Beth Harler Sells 1,708 Shares - MarketBeat
Igm biosciences principal accounting officer sells shares for $4,031 - Investing.com
Igm biosciences CEO sells $12,775 in stock - Investing.com
IGM Biosciences chief business officer sells shares worth $7,951 By Investing.com - Investing.com Canada
IGM Biosciences (NASDAQ:IGMS shareholders incur further losses as stock declines 21% this week, taking five-year losses to 84% - Simply Wall St
Brokerages Set IGM Biosciences, Inc. (NASDAQ:IGMS) Target Price at $17.75 - Defense World
IGM Biosciences, Inc. (NASDAQ:IGMS) Receives $17.75 Average Target Price from Analysts - MarketBeat
IGM Biosciences' SWOT analysis: stock pivot to autoimmune focus sparks analyst optimism - Investing.com Australia
IGM Biosciences' SWOT analysis: stock pivot to autoimmune focus sparks analyst optimism By Investing.com - Investing.com South Africa
BMO Capital Markets Begins Coverage on IGM Biosciences (NASDAQ:IGMS) - Defense World
IGM Biosciences (NASDAQ:IGMS) Shares Gap Up – Here’s What Happened - Defense World
IGM Biosciences (NASDAQ:IGMS) Shares Gap UpStill a Buy? - MarketBeat
BMO Capital Initiates Coverage of IGM Biosciences (IGMS) with Outperform Recommendation - MSN
IGM Biosciences (NASDAQ:IGMS) Coverage Initiated by Analysts at BMO Capital Markets - MarketBeat
BMO sets $21 target for IGM Biosciences with Outperform rating By Investing.com - Investing.com UK
IGM Biosciences: Dizzying Number Of Pivots (NASDAQ:IGMS) - Seeking Alpha
Quest Partners LLC Decreases Stock Position in IGM Biosciences, Inc. (NASDAQ:IGMS) - Defense World
IGM Biosciences (NASDAQ:IGMS) Shares Down 4.1%Should You Sell? - MarketBeat
How to Take Advantage of moves in (IGMS) - Stock Traders Daily
IGM Biosciences (NASDAQ:IGMS) Shares Gap DownHere's What Happened - MarketBeat
Brokerages Set IGM Biosciences, Inc. (NASDAQ:IGMS) Price Target at $16.13 - MarketBeat
IGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Will Imvotamab Data Propel IGM Biosciences To New Heights In 2025? - RTTNews
How To Trade (IGMS) - Stock Traders Daily
FMR LLC Increases Stake in IGM Biosciences Inc - GuruFocus.com
IGM Biosciences Insiders Who Sold Avert US$165m Market Cap Dip - Simply Wall St
Biotech firm backs off its focus on oncology research - The Business Journals
IGM Biosciences (NASDAQ:IGMS) Given New $27.00 Price Target at Stifel Nicolaus - MarketBeat
Igm Biosciences: Navigating Financial Challenges Amidst Early-Stage Antibody Development - MSN
IGM Biosciences Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
IGM Biosciences (NASDAQ:IGMS) Shares Down 7.8%Here's Why - MarketBeat
IGM Biosciences Inc (IGMS) Quarterly 10-Q Report - Quartz
IGM Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
IGM Biosciences, Inc. (IGMS) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
IGM Biosciences earnings missed by $0.21, revenue topped estimates - Investing.com UK
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
IGM Biosciences Reports $61.4M Loss, Extends Cash Runway to 2027 Despite Clinical Progress | IGMS Stock News - StockTitan
IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
IGM Biosciences to Present at Three Upcoming Investor Conferences - GlobeNewswire
(IGMS) Investment Report - Stock Traders Daily
IGM Biosciences (NASDAQ:IGMS) Shares Down 3.7%Should You Sell? - MarketBeat
Brokerages Set IGM Biosciences, Inc. (NASDAQ:IGMS) PT at $15.00 - Defense World
IGM Biosciences (NASDAQ:IGMS) Trading 7.7% HigherHere's Why - MarketBeat
IGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
IGM Biosciences' SWOT analysis: autoimmune pivot drives stock outlook - Investing.com India
Igm Biosciences Inc Stock (IGMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):